DOW JONES28,992.41-227.57 -0.78%
S&P 5003,337.75-35.48 -1.05%
NASDAQ9,576.59-174.38 -1.79%

Wedbush Downgrades Karyopharm Therapeutics to Neutral

Wedbush analyst David Nierengarten downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Outperform to Neutral.

Benzinga · 01/17/2020 12:34

Wedbush analyst David Nierengarten downgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Outperform to Neutral.